Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novartis Ag (GB:0K9E)
LSE:0K9E
Novartis (0K9E) Share Price & Analysis
1 Followers
0K9E Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$86.24 - $108.36
Previous Close$92.94
Volume1.27K
Average Volume (3M)26.15K
Market Cap
$184.56B
Enterprise Value$190.48B
Total Cash (Recent Filing)$14.43B
Total Debt (Recent Filing)$20.26B
Price to Earnings (P/E)N/A
Beta0.71
Next Earnings
Apr 23, 2024EPS Estimate
$1.67Last Dividend Ex-Date
Mar 07, 2024Dividend Yield3.43%
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,044,033,986
10 Day Avg. Volume23,733
30 Day Avg. Volume26,146
Standard Deviation0.06
R-Squared0.22
Alpha0.00416
Financial Highlights & Ratios
Price to Book (P/B)-53.62
Price to Sales (P/S)3.97
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.35
Enterprise Value/Gross Profit5.57
Enterprise Value/Ebitda23.21
Forecast
1Y Price Target
$111.50Price Target Upside19.97% Upside
Rating ConsensusHold
Number of Analyst Covering5
Novartis News
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyNovartis has the financial capacity for strategic acquisitions that could enhance its portfolio and drive future growth.
Growth StrategyNovartis is well-positioned for long-term growth following the Sandoz spinoff, poised to streamline operations and focus on core areas.
Product PipelineNovartis maintains a clinical pipeline that includes label expansion efforts and the development of new molecular entities to offset upcoming loss of exclusivities.
Bears Say
Market CompetitionLow visibility into competitive dynamics for key products could lead to downward adjustments in future sales forecasts.
Stock ValuationTarget price implies modest upside to current levels, indicating limited growth potential in the near term.
Stock ValuationThe analyst's target price implies modest upside from current levels, suggesting limited growth potential in the near term.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.00% Mutual Funds
0.19% Other Institutional Investors
99.81% Public Companies and
Individual Investors
0K9E FAQ
What was Novartis Ag’s price range in the past 12 months?
Novartis Ag lowest share price was $86.24 and its highest was $108.36 in the past 12 months.
What is Novartis Ag’s market cap?
Currently, no data Available
When is Novartis Ag’s upcoming earnings report date?
Novartis Ag’s upcoming earnings report date is Apr 23, 2024 which is in 5 days.
How were Novartis Ag’s earnings last quarter?
Novartis Ag released its earnings results on Jan 31, 2024. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.651 by -$0.121.
Is Novartis Ag overvalued?
According to Wall Street analysts Novartis Ag’s price is currently Undervalued.
Does Novartis Ag pay dividends?
Novartis Ag pays a Annually dividend of $2.46 which represents an annual dividend yield of 3.43%. See more information on Novartis Ag dividends here
What is Novartis Ag’s EPS estimate?
Novartis Ag’s EPS estimate is $1.67.
How many shares outstanding does Novartis Ag have?
Currently, no data Available
What happened to Novartis Ag’s price movement after its last earnings report?
Novartis Ag reported an EPS of $1.53 in its last earnings report, missing expectations of $1.651. Following the earnings report the stock price went down -2.826%.
Which hedge fund is a major shareholder of Novartis Ag?
Among the largest hedge funds holding Novartis Ag’s share is Dodge & Cox. It holds Novartis Ag’s shares valued at 1B.
---
Novartis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$111.50 (19.97% Upside)
$111.50 (19.97% Upside)
Blogger Sentiment
Bullish
GB:0K9E Sentiment 82%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.86%
12-Months-Change
Fundamentals
Return on Equity
16.52%
Trailing 12-Months
Asset Growth
-14.73%
Trailing 12-Months
Company Description
Novartis Ag
Novartis AG develops, manufactures and sells healthcare products. Its two reporting segments are: Innovative Medicines and Sandoz. The Innovative Medicines business develops and sells patented prescription medicines and is made up of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
---
0K9E Company Deck
---
0K9E Earnings Call
Q4 2024
0:00 / 0:00
---
0K9E Stock 12 Months Forecast
Average Price Target
$111.50
▲(19.97% Upside)
Technical Analysis
Best Analysts Covering 0K9E
1 Year
1 Year Success Rate
5/8 ratings generated profit
1 Year Average Return
+11.60%
reiterated a buy rating 7 months ago
Copying Graham Parry's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +11.60% per trade.
---